Hypovolemia: Used to restore and maintain circulating blood volume when there is a proven volume deficit and colloid therapy is suitable.

Hypoalbuminemia: Indicated in severe albumin deficiency due to illness or active bleeding. In cases of protein loss, its effect may be temporary unless the underlying cause is corrected.

Prevention of Central Volume Depletion after Paracentesis due to Cirrhotic Ascites: Used to support cardiovascular stability after removal of large volumes of ascitic fluid in cirrhosis.

Ovarian Hyperstimulation Syndrome (OHSS): Acts as a plasma expander in managing severe OHSS.

Adult Respiratory Distress Syndrome (ARDS): Used along with diuretics to manage fluid overload in ARDS.

Burns: Indicated after 24 hours post-burn in patients with significant albumin loss to reduce edema.

Hemodialysis: Used in patients undergoing long-term dialysis or those with fluid overload who cannot tolerate large volumes of saline.

Cardiopulmonary Bypass: Used during bypass procedures to assist in fluid management.

Human albumin is a plasma protein with the lowest molecular weight among major plasma proteins (approximately 66,241 Daltons). Due to its structure, albumin solutions have lower viscosity compared to other plasma proteins, which facilitates cardiac function. Albumin constitutes more than half of total plasma protein and about 10% of protein synthesized in the liver. Approximately 40% remains within circulation, while the rest is distributed in extravascular spaces such as muscle, skin, and intestines. Albumin produces about 25% of plasma oncotic pressure and plays a major role in maintaining fluid balance. It contributes approximately 75% of the normal oncotic pressure in blood vessels. Additional roles include binding and transport of molecules like hormones, enzymes, drugs, and toxins; antioxidant effects through free radical scavenging; influence on platelet function and clotting; and regulation of capillary permeability.

Hypovolemia: Adults Initial dose of 25 g is suggested. Pediatric dosage should be adjusted based upon on age, weight and clinical conditions.

Hypoalbuminemia: 50–75 g

Prevention of Central Volume Depletion after Paracentesis due to Cirrhotic Ascites: 6–8 g for every 1000 mL of ascitic fluid removed

OHSS Adults: Adults 50–100 g over 4 hours and repeated at 4–12 hour intervals as necessary. 10–50 g: single infusion

ARDS: Adults 25 g over 30 minutes and repeated at 8 hours for 3 days if necessary.

Burns: The amount of albumin required to achieve adequate plasma volume and protein content should be determined by direct observation of vital signs or measurement of either plasma oncotic pressure or protein content

Hemodialysis: 100 ml

Cardiopulmonary Bypass: Required dose can be estimated from the difference between the desired and actual total serum protein concentration multiplied by the estimated plasma volume (approximately 40 mL per kg) times 2 (to account for extravascular deficit, which absorbs about half of the administered dose).

Human albumin should not be mixed directly with other medicinal products, including blood or blood components. However, it may be administered alongside compatible parenteral fluids such as whole blood, plasma, saline, glucose, or sodium lactate when required. It should not be combined with protein hydrolysates or alcohol-containing solutions, as this may lead to protein precipitation.

Human albumin is contraindicated in patients with known hypersensitivity to albumin, its excipients, or container components. It is also not recommended in patients with severe anemia or heart failure.

Common side effects include flushing, urticaria, fever, chills, nausea, vomiting, rapid heart rate, and low blood pressure. These reactions usually subside when the infusion rate is reduced or stopped. In severe cases such as shock or anaphylaxis, treatment must be discontinued immediately and appropriate measures taken.

There is insufficient data to determine the safety of human albumin during pregnancy or breastfeeding. It is not known whether it can cause fetal harm or is excreted in breast milk.

Use with caution in patients with hypertension, low cardiac reserve, or dehydration. Monitor for signs of circulatory overload, especially in critically ill or postoperative patients. There is a potential risk of transmission of infectious agents. The dosage and infusion rate should always be individualized based on the patient's condition.

Pediatric Use: Adult doses may be used in children aged 12–16 years. For children under 12 years, clinical data is limited and dosing should be adjusted based on body weight and condition. Typically, one-fourth to half of the adult dose is used, and infusion rates should be lower. Physicians should carefully evaluate risks and benefits in pediatric patients.

Excessive dosing or rapid infusion may lead to hypervolemia. Early signs include headache, breathing difficulty, increased venous pressure, hypertension, and pulmonary edema. In such cases, infusion should be stopped and the patient monitored carefully, with appropriate supportive measures taken.

Plasma expanders.

Store below 30°C, protected from light and moisture. Keep out of reach of children.